2018 ASCO GU Public

Maha Hussain, MD, FACP, FASCO, presenting Abstract 4, "PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC)," during Oral Abstract Session A: Prostate Cancer

San Francisco, CA - 2018 Genitourinary Cancers Symposium - Maha Hussain, MD, FACP, FASCO, presenting Abstract 4, "PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC)," during Oral Abstract Session A: Prostate Cancer at the 2018 Genitourinary Cancers Symposium in San Francisco, CA, here today, Thursday February 8, 2018. The conference is the premier meeting on the science and treatment of Genitourinary Cancers from basic research to patient-based studies to larger clinical trials and population analyses in the United States. More than 3,000 experts from around the world are attending the meeting which is sponsored by the American Society of Clinical Oncology, the American Society of Radiation Oncology, and the Society of Urologic Oncology. Photo by © ASCO/Todd Buchanan 2018